ERBB2 and neoplasm: Agreed with the reported partial tumor growth inhibition by RT combined with blocking CD4750,53, a similar insufficiency in tumor growth inhibition was observed by RT combined with an antibody blocking either CD47 or HER2 or with CRISPR-mediated gene deficiency.